Lisa Conte, President and CEO of Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high-value horses, and the interim CEO of Napo Pharmaceuticals, Inc. (“Napo”), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, will participate in the invitation-only Monaco Growth Forums Ltd. (“MGF”) roadshow and conference, the Monaco Growth Forums Spring Edition, April 24th at the Mondrian Hotel in London, England, and from April 25th-26th at The Metropole Hotel in Monte Carlo, Monaco.

Jaguar is engaged in the development of a pipeline of prescription drug product candidates and non-prescription products to address unmet needs in animal health. Jaguar’s pipeline currently includes prescription drug product candidates for nine indications across multiple species, including the treatment of acute diarrhea in dogs and cats, and non-prescription products targeting seven species including adult horses, dairy calves, piglets, and other farm/production animals.

Napo’s proprietary, patented gastrointestinal compound, crofelemer, is a first-in-class anti-secretory agent. Napo launched Mytesi™ (crofelemer 125mg delayed-release tablets), a human drug approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, in October 2016.

Crofelemer is also the active pharmaceutical ingredient in Canalevia™, Jaguar’s lead prescription drug product candidate for companion animals, which is being evaluated for treatment of acute diarrhea and chemo-therapy induced diarrhea (“CID”) in dogs and is the subject of a recently forged collaboration between Jaguar and Elanco US Inc., a subsidiary of Eli Lilly and Company. Jaguar expects to conduct the commercial launch of Canalevia™ for the CID indication in the next year.

“I look forward to presenting at this event to familiarize investors with Jaguar and Napo and our shared mission to change the standard of care for gastrointestinal disease around the world. Mytesi™ has great depth of pipeline with multiple anticipated follow-up indications, most of which are supported by Phase 2 clinical testing. And the Jaguar portfolio also brings great breadth of pipeline, as we have executed on clinical development for diarrhea diseases in dogs, dairy calves, pigs, and foals, with more to come,” commented Conte.

As announced March 31, 2017, Jaguar and Napo have entered a definitive merger agreement.

For more information or to RSVP for the MGF Spring Conference event or schedule one-on-one investor meetings with Jaguar Animal Health, contact Sevinc Bermek, Events Coordinator at sbermek@monacogrowthforums.com.

About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high-value horses. Canalevia™ is Jaguar’s lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company’s lead non-prescription products. Neonorm™ is a standardized botanical extract derived from the Croton lechleri tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs. For more information, please visit www.jaguaranimalhealth.com.

About Napo Pharmaceuticals, Inc.
San Francisco-based Napo Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary pharmaceuticals for the global marketplace in collaboration with local partners. For more information, please visit www.napopharma.com.

About Monaco Growth Forums by Andreea Porcelli Ltd.
Monaco Growth Forums (MGF) is an exclusive, invitation-only conference highlighting growth companies seeking capital and/or greater exposure. Andreea Porcelli, MGF Founder, and President has more than 20 years experience as an international investment banker, finding investors for small cap companies on a world scale. She and her team select, by invitation-only, companies seeking international investor exposure to present and then socialize over three days with institutional fund managers, private asset managers, high-net-worth individuals, and industry-related sponsors and foundations—all of whom are also exclusively invited to match MFG’s highly selective criteria. www.monacogrowthforums.com

About Mytesi™
Mytesi™ (crofelemer 125mg delayed-release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi™. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%). Please see complete Prescribing Information available at Mytesi.com

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. These include statements regarding Jaguar’s expectation that it will conduct the commercial launch of Canalevia™ for the CID indication in the next year, the proposed merger between Jaguar and Napo, and Jaguar’s intention to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

X